Page 1

SUVEN PHARMA SUVEN PHARMACEUTICALS LTD Regd . Off : 3rd Floor , SDE Serene Chambers , Road No.5 , Banjara Hills , Hyderabad - 500 034 STATEMENT OF UN - AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & SIX MONTHS ENDED 30th SEPTEMBER , 2021 . Rs . In Lakhs PART - I STANDALONE For the year For the Quarter Ended Sl . No. PARTICULARS 30/09/2021 UN - AUDITED 30/06/2021 UN - AUDITED ( 1 ) ( 2 ) 30/09/2020 UN - AUDITED ( 3 ) For 6 Months Ended 30/09/2021 UN - AUDITED ( 4 ) 30/09/2020 ended 31/03/2021 UN - AUDITED ( 5 ) Audited ( 6 ) 1 Income Revenue from operations 30,098.83 26,380.13 23,738.81 56,478.96 47,562.05 100,971.85 Other Income 3,833.50 Total income 33,932.33 578.29 26,958.42 35.68 23,774.49 4,411.79 60,890.75 609.59 48,171.64 1,423.70 102,395.55 2 Expenses a ) Cost of materials consumed 11,885.90 9,183.96 7,717.95 21,069.86 14,318.22 31,031.50 b ) Purchases of stock - in - trade c ) Changes in inventories of finished goods , work - in - progress and stock - in- trade ( 2,628.34 ) ( 1,508.91 ) ( 355.65 ) ( 4,137.25 ) 118.99 d ) Employee benefits expense 2,319.43 2,115.89 2,092.90 4,435.32 3,837.32 ( 837.30 ) 7,623.30 e ) R & D expense 366.94 235.24 381.42 602.18 689.27 1,105.75 f ) Finance costs 117.51 212.55 264.31 330.06 536.31 914.37 g ) Depreciation and amortisation expenses 917.70 899.33 750.02 1,817.03 1,456.36 3,163.58 h ) Manufacturing Expenses 4,373.88 3,884.83 2,970.64 8,258.71 5,359.35 13,378.94 i ) Other Expenses 1,603.51 1,007.47 1,144.20 2,610.98 2,289.43 4,617.49 Total expenses 18,956.53 16,030.36 14,965.79 34,986.89 28,605.25 60,997.63 Profit before exceptional items & 3 Tax ( 1-2 ) 14,975.80 10,928.06 8,808.70 25,903.86 19,566.39 41,397.92 456 4 Exceptional Items Profit before Tax ( 3-4 ) 14,975.80 10,928.06 8,808.70 25,903.86 19,566.39 41,397.92 Tax Expenses a ) Current tax 3,278.01 b ) Deferred tax 178.03 2,716.35 67.59 2,163.92 111.78 5,994.36 245.62 4,892.64 17.75 10,171.51 361.72 Net Profit / ( Loss ) for the 7 period / year ( 5-6 ) 11,519.76 8,144.12 6,533.00 19,663.88 14,656.00 30,864.69 8 Other Comprehensive Income ( i ) Items that will not be 8.a reclassified to profit or loss ( 27.98 ) ( 27.96 ) ( 27.32 ) ( 55.94 ) ( 54.65 ) ( 111.85 ) ( ii ) Income tax relating to items that will not be reclassified to profit or loss 7.05 7.03 6.88 14.08 13.76 28.15 ( i ) Items that will be reclassified 8.b to profit or loss ( ii ) Income tax relating to items that will be reclassified to profit or loss Total other Comprehensive Income ( 20.93 ) ( 20.93 ) ( 20.44 ) ( 41.86 ) ( 40.89 ) ( 83.70 ) Total Comprehensive Income for 9 the period ( 7 + 8 ) 10 Paid - up equity share capital Face Value of the Share 11,498.83 2,545.65 Re . 1.00 8,123.19 2,545.65 Re . 1.00 6,512.56 2,545.65 Re . 1.00 19,622.02 2,545.65 Re . 1.00 14,615.11 2,545.65 Re . 1.00 30,780.99 2,545.65 11 Other Equity Re . 1.00 103,972.68 Earning Per Share ( EPS ) ( Face 12 value of Rs . 1 / - each ) a ) Basic b ) Diluted 4.53 4.53 3.20 3.20 2.57 2.57 ( not annualised ) ( not annualised ) ( not annualised ) ( not annualised ) 7.72 7.72 5.76 5.76 ( not annualised ) 12.12 12.12 ( annualised )